

Senate Community Affairs Committee

ANSWERS TO ESTIMATES QUESTIONS ON NOTICE

HEALTH AND AGEING PORTFOLIO

Budget Estimates 2012-2013, 30 & 31 May and 1 June 2012

Question: E12-072

OUTCOME 1: Population Health

Topic: RU486

Type of Question: Hansard Page 49, 31 May 2012

Number of pages: 1

Senator: Senator Boswell

Question:

Is the TGA aware that the FDA strongly recommends against the vaginal administration of Mifopristol in association with the use of RU486?

Answer:

As at 19 July 2011, post market safety information for Mifeprex (mifepristone) published on the US Food and Drug Administration (FDA) website states:

“The safety and effectiveness of other Mifeprex dosing regimens, including use of oral misoprostol tablets intravaginally, has not been established by the FDA”.